<?xml version='1.0' encoding='utf-8'?>
<document id="23631744"><sentence text="Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha."><entity charOffset="82-94" id="DDI-PubMed.23631744.s1.e0" text="atorvastatin" /><entity charOffset="99-167" id="DDI-PubMed.23631744.s1.e1" text="5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid" /><entity charOffset="169-178" id="DDI-PubMed.23631744.s1.e2" text="CP-778875" /><pair ddi="false" e1="DDI-PubMed.23631744.s1.e0" e2="DDI-PubMed.23631744.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23631744.s1.e0" e2="DDI-PubMed.23631744.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23631744.s1.e0" e2="DDI-PubMed.23631744.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23631744.s1.e1" e2="DDI-PubMed.23631744.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23631744.s1.e1" e2="DDI-PubMed.23631744.s1.e2" /></sentence><sentence text="1" /><sentence text=" 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), an agonist of the peroxisome proliferator-activated receptor alpha, has been evaluated in the clinic to treat dyslipidemia and type 2 diabetes mellitus"><entity charOffset="1-69" id="DDI-PubMed.23631744.s3.e0" text="5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid" /></sentence><sentence text=" Herein, we investigate the effect of CP-778875 on the pharmacokinetics of atorvastatin acid and its metabolites in humans"><entity charOffset="75-92" id="DDI-PubMed.23631744.s4.e0" text="atorvastatin acid" /></sentence><sentence text=" 2" /><sentence text=" The study incorporated a fixed-sequence design conducted in two groups" /><sentence text=" Group A was designed to estimate the effects of multiple doses of CP-778875 on the single dose pharmacokinetics of atorvastatin"><entity charOffset="116-128" id="DDI-PubMed.23631744.s7.e0" text="atorvastatin" /></sentence><sentence text=" Subjects in group A (n = 26) received atorvastatin (40 mg) on days 1 and 9 and CP-778875 (1"><entity charOffset="39-51" id="DDI-PubMed.23631744.s8.e0" text="atorvastatin" /></sentence><sentence text="0 mg QD) on days 5-12" /><sentence text=" Group B was designed to examine the effects of multiple doses of atorvastatin on the single dose pharmacokinetics of CP-778875"><entity charOffset="66-78" id="DDI-PubMed.23631744.s10.e0" text="atorvastatin" /></sentence><sentence text=" Subjects in group B (n = 29) received CP-778875 (0"><entity charOffset="39-48" id="DDI-PubMed.23631744.s11.e0" text="CP-778875" /></sentence><sentence text="3 mg) on days 1 and 9 and atorvastatin (40 mg QD) on days 5-12"><entity charOffset="26-38" id="DDI-PubMed.23631744.s12.e0" text="atorvastatin" /></sentence><sentence text=" 3" /><sentence text=" Mean maximum serum concentration (Cmax) and area under the curve of atorvastatin were increased by 45% and 20%, respectively, upon co-administration with CP-778875"><entity charOffset="69-81" id="DDI-PubMed.23631744.s14.e0" text="atorvastatin" /></sentence><sentence text=" Statistically significant increases in the systemic exposure of ortho- and para-hydroxyatorvastatin were also observed upon concomitant dosing with CP-778875" /><sentence text=" CP-778875 pharmacokinetics, however, were not impacted upon concomitant dosing with atorvastatin"><entity charOffset="85-97" id="DDI-PubMed.23631744.s16.e0" text="atorvastatin" /></sentence><sentence text=" 4" /><sentence text="  Inhibition of organic anion transporting polypeptide 1B1 by CP-778875 (IC50 = 2" /><sentence text="14 ± 0" /><sentence text="40 μM) could be the dominant cause of the pharmacokinetic interaction as CP-778875 did not exhibit significant inhibition of cytochrome P450 3A4/3A5, multidrug resistant protein 1 or breast cancer resistant protein, which are also involved in the hepatobiliary disposition of atorvastatin"><entity charOffset="276-288" id="DDI-PubMed.23631744.s20.e0" text="atorvastatin" /></sentence><sentence text="" /></document>